Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

Takeru Asano, Ken-ichi Matsuoka, Satoshi Iyama, Kazuteru Ohashi, Yoshihiro Inamoto, Chikako Ohwada, Makoto Murata, Atsushi Satake, Chikamasa Yoshida, Koichi Nakase, Yasuo Mori, Mitsune Tanimoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

Original languageEnglish
Pages (from-to)429-433
Number of pages5
JournalActa Medica Okayama
Volume70
Issue number5
Publication statusPublished - 2016

Fingerprint

Graft vs Host Disease
Grafts
Refractory materials
Interleukin-2
Stem cells
Hematopoietic Stem Cell Transplantation
Adrenal Cortex Hormones
Therapeutics
Clinical Trials, Phase I
Steroids
Survivors

Keywords

  • Allogeneic HSCT
  • Chronic GVHD
  • IL-2
  • Steroid refractory

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease. / Asano, Takeru; Matsuoka, Ken-ichi; Iyama, Satoshi; Ohashi, Kazuteru; Inamoto, Yoshihiro; Ohwada, Chikako; Murata, Makoto; Satake, Atsushi; Yoshida, Chikamasa; Nakase, Koichi; Mori, Yasuo; Tanimoto, Mitsune.

In: Acta Medica Okayama, Vol. 70, No. 5, 2016, p. 429-433.

Research output: Contribution to journalArticle

Asano, T, Matsuoka, K, Iyama, S, Ohashi, K, Inamoto, Y, Ohwada, C, Murata, M, Satake, A, Yoshida, C, Nakase, K, Mori, Y & Tanimoto, M 2016, 'Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease', Acta Medica Okayama, vol. 70, no. 5, pp. 429-433.
Asano, Takeru ; Matsuoka, Ken-ichi ; Iyama, Satoshi ; Ohashi, Kazuteru ; Inamoto, Yoshihiro ; Ohwada, Chikako ; Murata, Makoto ; Satake, Atsushi ; Yoshida, Chikamasa ; Nakase, Koichi ; Mori, Yasuo ; Tanimoto, Mitsune. / Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease. In: Acta Medica Okayama. 2016 ; Vol. 70, No. 5. pp. 429-433.
@article{7b24067bea9540a083cb58cef6f2f475,
title = "Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease",
abstract = "Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.",
keywords = "Allogeneic HSCT, Chronic GVHD, IL-2, Steroid refractory",
author = "Takeru Asano and Ken-ichi Matsuoka and Satoshi Iyama and Kazuteru Ohashi and Yoshihiro Inamoto and Chikako Ohwada and Makoto Murata and Atsushi Satake and Chikamasa Yoshida and Koichi Nakase and Yasuo Mori and Mitsune Tanimoto",
year = "2016",
language = "English",
volume = "70",
pages = "429--433",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

AU - Asano, Takeru

AU - Matsuoka, Ken-ichi

AU - Iyama, Satoshi

AU - Ohashi, Kazuteru

AU - Inamoto, Yoshihiro

AU - Ohwada, Chikako

AU - Murata, Makoto

AU - Satake, Atsushi

AU - Yoshida, Chikamasa

AU - Nakase, Koichi

AU - Mori, Yasuo

AU - Tanimoto, Mitsune

PY - 2016

Y1 - 2016

N2 - Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

AB - Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

KW - Allogeneic HSCT

KW - Chronic GVHD

KW - IL-2

KW - Steroid refractory

UR - http://www.scopus.com/inward/record.url?scp=84997706260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997706260&partnerID=8YFLogxK

M3 - Article

C2 - 27777442

AN - SCOPUS:84997706260

VL - 70

SP - 429

EP - 433

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -